Bidil Related Published Studies
Well-designed clinical trials related to Bidil (Hydralazine Hydrochloride / Isosorbide Dinitrate)
Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial). [2007.08.15]
Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. [2007.06]
Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. [2007.04.03]
A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. [2006.05]
Well-designed clinical trials possibly related to Bidil (Hydralazine Hydrochloride / Isosorbide Dinitrate)
Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A-HeFT). [2011.07]
Treatment of heart failure in African Americans--a call to action. [2011.02]
Treatment of heart failure in African Americans--a call to action. [2011]
Heart failure in the ethnic minorities. [2010.03]
Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial. [2009.12]
Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. [2009.04]
Other research related to Bidil (Hydralazine Hydrochloride / Isosorbide Dinitrate)
Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all
hospitalizations and on 30-day readmission rates in patients with heart failure:
results from the African-American Heart Failure Trial. [2014]
Current perspectives on hydralazine and nitrate therapies in heart failure. [2014]
Hydralazine does not ameliorate nitric oxide resistance in chronic heart failure. [2010.04]
Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A. [2010.03]
Hydralazine does not ameliorate nitric oxide resistance in chronic heart failure. [2010]
Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure. [2009.09]
Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. [2009.04.15]
Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure. [2009.03]
Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure. [2008.12]
Flaws in the U.S. Food and Drug Administration's rationale for supporting the development and approval of BiDil as a treatment for heart failure only in black patients. [2008.09]
Popular representations of race: the news coverage of BiDil. [2008.09]
"Special treatment": BiDil, Tuskegee, and the logic of race. [2008.09]
Genotyping the future: scientists' expectations about race/ ethnicity after BiDil. [2008.09]
Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage? [2008.09]
Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure. [2007.03]
BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective. [2007.01.02]
BiDil for heart failure in black patients: implications of the U.S. Food and Drug Administration approval. [2007.01.02]
Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. [2007.01.02]
BiDil (isosorbide dinitrate and hydralazine): a new fixed-dose combination of two older medications for the treatment of heart failure in black patients. [2007.01]
Lack of Bioequivalence between Different Formulations of Isosorbide Dinitrate and Hydralazine and the Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine: The V-HeFT Paradox. [2007]
Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial. [2007]
Fixed combination isosorbide dinitrate-hydralazine for nitric-oxide-enhancing therapy in heart failure. [2006.12]
BiDil: assessing a race-based pharmaceutical. [2006.11]
Race, pharmacogenomics, and marketing: putting BiDil in context. [2006.09]
BiDil: from another vantage point. [2006.09]
Prescribing BiDil: is it black and white? [2006.07.04]
Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure. [2006]
Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. [2005.12.30]
Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. [2005.12.13]
Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety. [2005.11]
Effects of nitrates and hydralazine in heart failure: clinical evidence before the african american heart failure trial. [2005.10.10]
Other possibly related research studies
Race, money and medicines. [2006.09]
The use of race and ethnicity in medicine: lessons from the African-American Heart Failure Trial. [2006.09]
Outcomes by gender in the African-American Heart Failure Trial. [2006.12.05]
Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial. [2006.09.19]
Pharmacological treatment of chronic heart failure. [2006.06]
A-HeFT: old dog, new endothelial tricks. [2005]
Combination pharmacologic therapies for heart failure: what next after angiotensin-converting enzyme inhibitors and beta-blockers? [2005.08]
The impact of race on response to RAAS inhibition. [2005.08]
Being specific about race-specific medicine. [2006.09]
There is no scientific rationale for race-based research. [2007.06]
African American heart failure trial: role of endothelial dysfunction and heart failure in African Americans. [2007.03.26]
Evidence-based treatment of chronic heart failure. [2007.03]
Pharmacologic management of heart failure caused by systolic dysfunction. [2008.04.01]
Gateways to clinical trials. [2008.01]
Emerging role of pharmacogenomics in heart failure. [2008.05]
Treatment of heart failure with normal left ventricular ejection fraction. [2007.01]
Hypertension and coronary artery disease: a summary of the American Heart Association scientific statement. [2007.10]
Treatment of heart failure with abnormal left ventricular systolic function in the elderly. [2007.02]
[Recent findings on nitrates: their action, bioactivation and development of tolerance] [2008.10]
Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers. [2008.07]
Pharmaceutical meaning-making beyond marketing: racialized subjects of generic thiazide. [2008.09]
Pharmacogenetics, race and global injustice. [2008.08]
Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial. [2008.11]
Heart failure in women: a need for prospective data. [2009.08.04]
Amiodarone-induced neurotoxicity. [2009.03.15]
Racial differences in heart failure therapeutics. [2010.01]
Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the Genetic Risk Assessment in Heart Failure substudy. [2009.11]
Primary care physicians' attitudes regarding race-based therapies. [2010.05]
A retrospective, observational cohort analysis of a nationwide database to compare heart failure prescriptions and related health care utilization before and after publication of updated treatment guidelines in the United States. [2010.08]
Nitrates for acute heart failure syndromes. [2013]
|